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Pyrimethamine pharmacokinetics were studied in 11 human immunodeficiency virus (HIV)-positive patients
who were seropositive for exposure to Toxoplasma gondii and were taking zidovudine (AIDS Clinical Trials
Group Protocol 102). Pyrimethamine was administered at 50 mg daily for 3 weeks to achieve steady state, and
pharmacokinetic profiles were determined after administration of the last dose. Noncompartmental and com-
partmental analyses were performed. Population pharmacokinetic analysis assuming a one-compartment mod-
el yielded the following estimates: area under the 24-h concentration-time curve, 42.7 6 12.3 mg z h/ml; half-
life, 1396 34 h; clearance, 1.286 0.41 liters/h; volume of distribution, 2466 64 l; and absorption rate constant,
1.5 6 1.3 liters/h. These values are similar to those seen in subjects without HIV infection. Pyrimethamine
pharmacokinetics did not differ significantly in those subjects who were intravenous drug users. Adverse effects
were noted in 73% of those initially enrolled in this study, leading to discontinuation for 38%. No association
was noted between pyrimethamine levels and the incidence of adverse events. No significant differences were
seen in zidovudine pharmacokinetic parameters obtained from studies performed before and during treatment
with pyrimethamine. In summary, pyrimethamine exhibited pharmacokinetics in HIV-infected patients that
were similar to those in non-HIV-infected subjects and it did not alter the pharmacokinetics of zidovudine in
these patients.
Toxoplasma encephalitis is the most common opportunistic
infection causing focal brain disease in patients with AIDS (13,
16). The incidence of toxoplasmic encephalitis is directly pro-
portional to the prevalence of antibodies to Toxoplasma gondii
in any given population (15). Over 95% of toxoplasmic enceph-
alitis cases are due to reactivation of a chronic (latent) infec-
tion, usually when the CD4 lymphocyte count falls below 200/
mm3. In the United States, 10 to 40% of adults with AIDS are
latently infected and it is estimated that 30% of these patients
will develop toxoplasmic encephalitis (7, 14).
Pyrimethamine [2,4-diamino-5-(p-chlorophenyl)-6-ethyl-
pyrimidine] in combination with a sulfonamide is the standard
therapeutic regimen for toxoplasmic encephalitis (12). Oral
folinic acid is added to preclude the hematologic toxicity as-
sociated with pyrimethamine. A clinical response with this
combination has been reported in 68 to 95% of patients with
toxoplasmic encephalitis (8, 16). Unfortunately, high toxicity
rates have led to the discontinuation of therapy in up to 40%
of patients (8, 14). The adverse effects of pyrimethamine are
commonly dose-related cytopenias and rash, whereas the ad-
verse effects of sulfonamides include rash, nausea, cytopenia,
and nephrotoxicity, including crystalluria, hematuria, radiolu-
cent stones, interstitial nephritis, and renal failure. The com-
bination of oral pyrimethamine and oral or parenteral clinda-
mycin seems comparable in efficacy to pyrimethamine plus
sulfonamides (4, 9, 14) and is the recommended alternative
regimen for a sulfa-intolerant patient. Again, the incidence of
adverse effects, including nausea, vomiting, diarrhea, rash,
neutropenia, and pseudomembranous colitis, is high. Alterna-
tive therapeutic options are limited. To date, there is no in-
formation correlating serum drug concentrations with toxici-
ties.
An understanding of the pharmacokinetics of pyrimeth-
amine in patients with AIDS could be helpful in developing
treatment regimens that minimize the side effects but maintain
efficacy. Little information is currently available. Two studies
of patients with AIDS being treated for toxoplasma encepha-
litis suggested that the half-lives of pyrimethamine in serum
were much shorter than those typically found in noninfected
individuals. In one study, half-lives of 22.7 and 36.2 h were
found in the two patients fully evaluated (24). In the other, the
peak and trough values reported allowed the calculation of
half-lives ranging from 33 to 84 h (11). Half-lives in healthy
human immunodeficiency virus (HIV)-negative patients have
ranged from 35 to 175 h (24), with reported averages of 83 (2)
and 111 (18) h. In addition, little is known of the drug inter-
action between pyrimethamine and zidovudine, the mainstay
of HIV treatment.
We undertook an open-label, steady-state pharmacokinetic
study of pyrimethamine in HIV-infected patients seropositive
for exposure to T. gondii. We used the standard 50-mg daily
dose recommended for treating toxoplasma encephalitis. In
addition, we studied the effects of pyrimethamine on zidovu-
dine pharmacokinetics.
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MATERIALS AND METHODS
Subjects. Twenty-six patients were enrolled in the National Institute of Allergy
and Infectious Diseases AIDS Clinical Trials Group Protocol 102. Patients were
enrolled until 16 had completed the study treatment period (8 homosexual males
and 8 intravenous drug users; 13 from the Bronx Veterans’ Affairs Medical
Center and 3 from the University of North Carolina).
Eligible patients had laboratory evidence of HIV infection (positive antibody
enzyme-linked immunosorbent assay and Western blot [immunoblot], p24 anti-
gen, or culture) with an absolute CD4 lymphocyte count of #500/mm3 and
serological evidence of exposure to T. gondii (Sabin-Feldman dye, whole-cell
agglutination, or immunoglobulin G immunofluorescence test) but no clinical
manifestations of active toxoplasmic infection. They had been on a stable regi-
men of zidovudine ($500 mg/day) for at least 4 weeks and were continued on this
dosage for the duration of this study. All subjects were at least 18 years of age
and had a Karnofsky performance score of $60, total bilirubin of #1.5 mg/100
ml, serum aspartate aminotransferase activity of #3 times the upper limit of the
normal range, serum creatinine levels of,1.5 times the upper limit of the normal
range (or a calculated creatinine clearance of $50 ml/min for patients with
“wasting” syndrome), ,31 proteinuria, an absolute neutrophil count of .1,500/
mm3, and hemoglobin levels of $10.0 g/dl.
Patients were excluded if they had a history of prior toxoplasmic encephalitis
or of sensitivity to the study medications, had evidence of another serious op-
portunistic infection or central nervous system impairment, were unable to take
oral medication reliably, had a malabsorption syndrome, or were pregnant or
lactating. Patients were on a variety of medications during this study. However,
treatment with macrolides, sulfonamides, phenytoin, dapsone, immunomodula-
tors, amphotericin B, ganciclovir, probenecid, benzodiazepines, cytotoxic che-
motherapy, antifolates, other antiretroviral agents, and investigational agents
was forbidden within the 14 days prior to study entry and during this study. An
exception was made for patient 8, who was started on erythromycin on day 14.
Study design. All patients received an oral loading dose of 200 mg of py-
rimethamine on day 1. Subsequently, patients took 50 mg of pyrimethamine (two
25-mg tablets) and 10 mg of oral folinic acid daily for 21 days, as well as
zidovudine in the dose prescribed prior to enrollment. Trough levels of py-
rimethamine (drawn immediately before administration of the daily dose) were
obtained weekly during this study.
An initial study of zidovudine pharmacokinetics was performed prior to the
administration of pyrimethamine on day 1. Serum specimens for drug analysis
were obtained immediately before oral intake of zidovudine and at 0.25, 0.5, 0.75,
1.0, 1.5, 2.0, 3.0, and 4.0 h afterwards. The pharmacokinetics of both zidovudine
and pyrimethamine were studied after 21 days of pyrimethamine therapy, during
which a steady state was achieved. Serum specimens were drawn just prior to a
final oral dose of pyrimethamine and at 0.25, 0.50, 0.75, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0,
8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 72.0, and 96.0 h afterwards.
Patient evaluation and follow-up. A complete medical history and physical
examination were performed within 1 week prior to study entry. A complete
blood cell count with differential, serum chemistries, and a pregnancy test for
women of child-bearing potential were performed within 2 weeks prior to entry.
At weekly intervals during this study, a brief history, physical examination,
complete blood cell count with differential, and serum chemistries were obtained.
Patients were hospitalized during the pharmacokinetic evaluations.
Patients who took less than 75% of the study therapy during a 2-week period,
as determined by pill count, were considered noncompliant and were discontin-
ued from this study. Patients who missed two consecutive clinic visits without
rescheduling were also considered noncompliant and were discontinued.
Toxicity management. Study therapy was discontinued permanently if patients
developed an absolute neutrophil count of less than 1,000/mm3 or a 50% reduc-
tion from the baseline count to less than 3,000/mm3, a platelet count of less than
75,000/mm3, serum aspartate aminotransferase activity of greater than 5 times
the upper limit of normal, a doubling of serum creatinine or an increase to .2.0,
or any other grade 2 toxicity other than fatigue, headache, or constipation, as
defined by the AIDS Clinical Trials Group standard table for grading the severity
of adverse experiences.
Blood was drawn for determination of the pyrimethamine concentration at the
time of any permanent discontinuation for toxicity. Patients discontinued from
study treatment received appropriate medical management. Clinical follow-up
and pertinent laboratory evaluations were repeated as needed until there was
final resolution or stabilization of toxicity.
Pharmacokinetic analyses. Pyrimethamine concentrations were measured by
high-performance liquid chromatography (HPLC). Interday coefficients of vari-
ation were 5.3% at 0.2 mg/ml, 1.4% at 0.75 mg/ml, and 2.0% at 2.5 mg/ml;
analytical recovery ranged from 97.9 to 103.5% (20). Zidovudine concentrations
were measured by ZDV-Trac radioimmunoassay (Incstar Corp., Stillwater,
Minn.) using in-house calibrators prepared by supplementing pooled human
serum (Scantibodies Laboratory, Santee, Calif.) with known amounts of zidovu-
dine (Sigma Chemical Co., St. Louis, Mo.). Interday coefficients of variation were
7.55% at 139 ng/ml and 7.44% at 1,334 ng/ml; analytical recovery was 101.5% at
both concentrations.
Both noncompartmental and compartmental analyses of pyrimethamine con-
centrations over time were performed. The compartmental analyses provide a
complementary interpretation of the data relative to noncompartmental tech-
niques. Zidovudine concentrations over time were analyzed by noncompartmen-
tal methods, and the effects of pyrimethamine on the pharmacokinetics of zido-
vudine were determined by applying a paired Student’s t test or signed rank test
to the difference in the various pharmacokinetic parameters before and after
pyrimethamine administration. The signed rank test was preferred in cases in
which a Shapiro-Wilk test indicated nonnormality. The interaction of pyrimeth-
amine with zidovudine was also analyzed separately in patients who used intra-
venous drugs and in nonusers.
Noncompartmental analyses. The terminal elimination rate constant (kel) was
estimated in a stepwise log-linear regression beginning with the last three ob-
servations. On the basis of this regression fit, a 95% forecast interval was con-
structed for an observation at the next preceding time. If the actual observed
concentration at this time fell within this forecast interval, a new log-linear
regression including this observation was performed; if not, the procedure was
terminated, and kel was calculated as the negative of the slope of the final line.
The forecast interval was the region for which the probability of an observation
was 0.95, assuming that the observation arose from the same mean linear rela-
tionship used to calculate the interval. Thus, the criterion used corresponded to
concluding that there was evidence to suggest a departure from the current line
if the concentration observed had a likelihood of less than 5% of having arisen
from the current mean linear relationship. The terminal elimination half-life
(t1/2) was determined as t1/2 5 ln(2)/kel.
The area under the concentration-time curve from 0 to 24 h (AUC0–24) was
calculated by using the trapezoidal rule, and the AUC extrapolated to infinite
time (AUC0–`) was determined by calculating the observed area by the trape-
zoidal rule and adding the extrapolated area from the last time point to infinity
(the final concentration divided by kel). Because no intravenous data were ob-
tained, it was not possible to estimate the bioavailability fraction (F). Thus, oral
clearance (CL/F) was calculated as CL/F 5 dose/AUC0–24, and the apparent
volume of distribution (V/F) during the elimination phase was calculated as
V/F 5 (CL/F)/kel.
Compartmental analyses. As a complementary adjunct to noncompartmental
analyses, serum concentrations were fitted to polyexponential equations repre-
senting first-order compartmental models with first-order absorption by using
nonlinear, weighted least-squares regression. All individuals were assumed to be
at steady state. Some investigators have suggested that pyrimethamine pharma-
cokinetics are best described by a two-compartment model (17, 25); here, some
subjects showed evidence of an apparent distributive phase while others did not.
Furthermore, a number of subject profiles contained apparent outliers (e.g., the
16-h time point in Fig. 1d). The concentrations of outliers were verified by repeat
HPLC analysis and, in some instances, by analysis using a methodologically
independent enzyme inhibition assay (20) to rule out interfering substances.
Other investigators have also noted substantial intraindividual fluctuations in
pyrimethamine concentrations (10). Consequently, while fits of a one-compart-
ment model were obtained for all patients, because of outlying observations
and/or the lack of a clear distributive phase, it was possible to obtain a conver-
gent nonlinear regression fit of the two-compartment model for only one patient.
Thus, formal model selection techniques could not be used to identify an overall
best-fitting model. Visual inspection of residual plots for the one-compartment
model showed evidence of lack of fit for only three patients (see Fig. 1b, c, and
d). On the basis of these considerations, a one-compartment model was used to
represent the kinetics of pyrimethamine. Although for the data from 3 patients
this model may have been an inadequate characterization, overall, it provided a
reasonable fit to the data for all 11 subjects. The model was parameterized
explicitly in terms of CL/F, V/F, and the absorption rate constant (ka). AUC0–24
and AUC0–` were calculated by integrating the fitted model from 0 to 24 h and
to infinity, respectively. The t1/2 was calculated as kel 5 (CL/F)/(V/F) by using the
estimated parameters for each subject.
By using a one-compartment model, a two-stage population pharmacokinetic
analysis was performed (1, 6, 23); this method of population analysis is best
suited to rich within-subject data. At the first stage, the model was fitted to
individual-subject data by nonlinear least squares. Because serum concentrations
typically exhibit heterogeneous within-subject variation, fitting usually incorpo-
rates a weighting scheme (1). Commonly, intrasubject variability is assumed to
follow a proportional error (constant coefficient of variation [CV]) model, i.e.,
variance of a concentration at time t is modeled as proportional to Cm(t)2, where
Cm(t) is mean concentration at t. Because of the substantial number of outlying
observations at high concentrations, weighted residual plots from fits using the
proportional error model still showed evidence of variance heterogeneity, sug-
gesting that the model did not fully take this phenomenon into account. Conse-
quently, a modified error model in which variance at t is taken to be proportional
to Cm(t)b for power b . 2 was considered; this model allows for more profound
increases in variance with mean. The power b was estimated from the data as 2.5
by standard statistical methods for the estimation of error models based on
residuals from all subjects (1, 5, 6). Nonlinear weighted least-squares regression
using this error model was then undertaken, and residual plots from this weigh-
ing indicated that the heterogeneity of variance was fully accommodated. At the
second stage, these weighted estimates and their estimated standard errors were
treated as data to estimate population characteristics (mean and standard devi-
ation [SD]) of the pharmacokinetic model by methods previously described in
detail (1, 6, 23). In this approach, a population model relating the estimate for
subject i (Pi) to the population mean (P) is fitted by weighted-regression tech-
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niques; i.e., the model is Pi 5 P 1 ei, where ei is a subject error incorporating
components of both uncertainty in Pi due to estimation (standard errors) and
variability in the population. This latter component and P are estimated from the
data. Population pharmacokinetic analysis assumes that subjects arise from a
population; however, the first-stage individual estimates are obtained separately
for each subject, so they do not take advantage of information on the population
in all the data. Thus, it is customary to obtain refined estimates of individual
pharmacokinetic parameters (6, 23), which represent each subject’s kinetics by a
weighted combination of the first-stage estimate and the estimate of the popu-
lation mean kinetics. These individual estimates are often referred to as empir-
ical Bayes estimates and are more precise than the first-stage estimates alone, as
they balance individual information against that about the population, and are
preferred to first-stage estimates for characterizing individual kinetics (22). Be-
cause of this weighing, empirical Bayes estimates have the added benefit of
countering the influence of individual patient outliers not enjoyed by first-stage
estimates; thus, they are a natural choice for these data.
RESULTS
Course of study treatment and adverse events. Twenty-six
patients meeting the eligibility criteria were enrolled in this
study between November 1990 and January 1992. Sixteen sub-
jects completed the full course of treatment; 10 discontinued
treatment because of adverse experiences. Four did so because
of nausea, four did so because of generalized skin eruptions
(associated with fever in three, anemia in one, and headaches
in one), and two did so because of headaches. An additional
nine patients developed adverse experiences but completed
the 21-day course of treatment. Thus, 19 of the 26 patients
entering this study experienced at least one adverse event. The
most common adverse events were nausea (11 patients), head-
aches (8), elevation of liver enzymes (7), skin eruptions (5), leu-
kopenia (5), fever (3), sore throat (3), and elevation of creatine
kinase (3 patients). Some patients experienced more than one
adverse event. Four of the seven patients with increased levels
of liver enzymes had mild elevations at study entry. Less fre-
quent adverse events included anemia, hyperuricemia, hyper-
calcemia, hypocalcemia, hyperkalemia, light-headedness, night
sweats, cough, chest pain, myalgias, earache, and blurred vision.
Serum creatinine levels increased in 23 patients after the
initiation of pyrimethamine therapy. The average serum cre-
atinine level rose from 1.08 6 0.17 mg/dl (n 5 26) at baseline
to 1.35 6 0.28 mg/dl (n 5 25) after 1 week of therapy. It re-
mained stable at 1.36 6 0.26 mg/dl (n 5 20) after 2 weeks and
fell slightly to 1.25 6 0.32 mg/dl after 3 weeks. Because of the
long t1/2 of pyrimethamine, substantial drug concentrations
remained at the end of this study and follow-up creatinine
concentrations were not obtained after complete CL of pyri-
methamine.
Mean trough pyrimethamine concentrations increased from
1.58 6 0.50 mg/ml (range, 0.45 to 2.34 mg/ml) after 1 week of
therapy to 1.78 6 0.59 mg/ml (range, 0.94 to 2.85 mg/ml) and
1.79 6 0.57 mg/ml (range, 0.80 to 2.92 mg/ml) after 2 and 3
weeks, respectively. The difference between the mean trough
values after 1 and 2 weeks was highly significant (P , 0.0001).
Pyrimethamine pharmacokinetics. (i) Noncompartmental
analysis. Complete pharmacokinetic data for pyrimethamine
were available for 12 patients. However, the profile for subject
11 was quite unusual; a sequence error in the labeling of
samples and unrecorded concomitant administration of other
medications are possible, but unverifiable, explanations. Al-
though pharmacokinetic parameters were calculated for this
subject, they were not comparable in magnitude to those for
the remaining subjects as a consequence of the unusual pattern
of observations. Accordingly, estimated pharmacokinetic pa-
rameters for this subject are excluded from Table 1, which
shows the results of noncompartmental analysis for the re-
maining 11 subjects. The estimated pyrimethamine CLs were
strongly and negatively correlated with the trough concentra-
tions measured at time zero (r 5 20.93) (data not shown).
(ii) Compartmental analysis. Fits of the one-compartment
model, assuming steady state, were conducted as described
above. Figure 1 shows both the first-stage weighted nonlinear
regression fits and the refined, empirical Bayes fits for four
patients, including the three with the most evidence of a dis-
tributive phase. The initial and refined profiles appear to be
quite similar, and the estimates of CL/F and AUC0–24 were
virtually identical. However, the initial and refined estimates of
V/F and ka were less consistent within individuals, particularly
those with large outliers; the latter estimates downweight the
influence of outlying data and are likely to be more reliable.
Accordingly, we report refined estimates to characterize indi-
vidual pharmacokinetics in Table 2. Because a population
pharmacokinetic analysis was conducted, the means, SDs, and
CVs reported in Table 2 are stage 2 estimates rather than
summary statistics for these 11 subjects.
Correlation of drug exposure with adverse effects. There was
insufficient evidence to suggest an association between higher
drug concentrations and the incidence of adverse effects. Be-
cause of the small number of subjects in this study, it was not
possible to conduct a detailed evaluation of the relationship
between particular adverse effects and pyrimethamine concen-
trations. However, by classifying subjects as tolerant if they ex-
perienced no toxicity and intolerant if they experienced one or
more adverse effects, of the 18 patients with week 1 trough lev-
els, the 5 tolerant patients had a median trough level of 1.74
mg/ml compared with 1.68 mg/ml for the 13 subjects intolerant
by week 1. At 2 weeks, the median trough levels for the 5 tolerant
patients and the 11 remaining intolerant patients were 1.89 and
1.74 mg/ml, respectively; at 3 weeks, the median trough levels
were 1.81 mg/ml (5 tolerant patients) and 1.87 mg/ml (6 intol-
erant patients). Note that five intolerant patients left this study
between weeks 2 and 3. Thus, these results should be interpret-
ed with caution, as median levels for the intolerant patients are
based only on patients that had not yet left this study. Among
the 11 patients remaining for pyrimethamine profiles to be ob-
tained at week 3, the median observed maximum concentra-
tions of pyrimethamine in serum were 2.14 and 2.23 mg/ml and
the median AUC0–24 values were 41.39 and 42.17 mg z h/ml for
the 5 tolerant and 6 intolerant patients, respectively.
Effects of intravenous drug use on pyrimethamine pharma-
cokinetics. To assess whether there were differences in drug
TABLE 1. Pyrimethamine pharmacokinetic parameters for
11 subjects estimated by noncompartmental analysis
Subject AUC0–24(mg z h/ml)
AUC0–`







1 32.51 323.35 154.01 1.5382 341.7629 1.611
2 54.02 938.60 305.59 0.9256 408.0889 2.474
3 41.60 342.00 123.73 1.2019 214.5393 2.277
4 23.40 119.27 81.08 2.1368 249.9546 1.110
5 45.41 658.32 231.84 1.1011 368.2874 2.295
6 50.22 425.99 137.66 0.9956 197.7332 2.587
7 63.25 574.53 136.33 0.7906 155.4911 3.021
8 34.24 258.61 113.54 1.4601 239.1778 1.745
9 44.27 413.08 141.69 1.1245 229.8699 2.140
10 25.17 268.50 186.33 1.9865 534.0174 1.237
12 45.68 1,209.94 484.32 1.0945 764.7669 2.160
Mean 41.82 502.93 190.56 1.3050 336.3990 2.059
SD 12.14 324.49 115.37 0.4322 179.9485 0.581
CV 0.29 0.65 0.61 0.3311 0.5344 0.282
a Cmax, maximum concentration observed.
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disposition for intravenous drug users compared with nonus-
ers, two-sample hypothesis tests (t test and two-sided Wilcoxon
test) were applied to the mean differences of each pharmaco-
kinetic parameter obtained from both noncompartmental and
compartmental analyses. For neither analysis was the evidence
strong enough to suggest a difference between the two groups
in any mean pharmacokinetic parameter value (data not shown).
Analysis of zidovudine-pyrimethamine-pharmacokinetic in-
teraction. Zidovudine concentration-time profiles before and
after the initiation of pyrimethamine treatment were available
for 11 patients. The profile of one patient was highly irregular
and was not included in this analysis. The population values for
zidovudine pharmacokinetic parameters without and with pyri-
methamine treatment are given in Table 3. Pharmacokinetic
profiles were obtained for all but one of the 10 patients listed
in Table 2 after a 100-mg dose both before and after pyrimeth-
amine; the remaining subject received a 200-mg dose on both
occasions, and concentrations were corrected to a dose of 100
mg for this patient. These values fall within the ranges of values
reported for zidovudine by other investigators. When values
without and with pyrimethamine were compared, no significant
differences in any of these parameters were detected by the
paired t test and the signed rank test (data not shown).
DISCUSSION
The primary focus of this study was to evaluate the pharma-
cokinetics of pyrimethamine administered daily to HIV-in-
fected patients on concurrent zidovudine therapy. A particular
concern was to confirm previous reports suggesting an in-
creased CL and a shorter t1/2 for pyrimethamine in HIV-in-
fected patients compared with those in uninfected persons,
since this could have a major impact on dosing recommenda-
tions. Another objective was to determine whether the high
FIG. 1. Pyrimethamine pharmacokinetics at steady state. Pyrimethamine was given to subjects at 50 mg daily for 3 weeks. Plots of serum pyrimethamine
concentrations at various times after administration of the final dose are shown for four representative subjects: subject 3 (a), subject 4 (b), subject 7 (c), and subject
8 (d). The calculated curve for first-stage analysis is shown as a solid line, and the refined, empirical Bayes fit is shown as a broken line.
TABLE 2. Pyrimethamine pharmacokinetic parameters for
11 subjects estimated by compartmental analysis
Subject AUC0–24(mg z h/ml)
AUC0–`







1 33.97 289.25 132.30 1.4716 280.8810 0.7872
2 52.83 611.80 183.75 0.9464 250.8733 1.4976
3 44.21 352.20 123.67 1.1310 201.7729 1.8278
4 23.34 113.14 71.25 2.1426 220.2571 0.8166
5 47.76 539.17 178.79 1.0469 270.0237 1.1929
6 50.30 435.12 135.12 0.9940 193.7630 2.2267
7 64.53 622.29 151.76 0.7748 169.6262 3.6241
8 36.19 255.72 108.52 1.3816 216.3202 1.3231
9 46.07 413.15 139.93 1.0852 219.0596 1.6533
10 24.49 199.10 124.88 2.0418 367.8754 0.3522
12 45.57 524.92 182.50 1.0971 288.8637 1.0088
Mean 42.66 395.90 139.32 1.2798 245.6278 1.5478
SD 12.29 169.84 34.14 0.4141 63.8332 1.3394
CV 0.29 0.43 0.25 0.3235 0.2598 0.8653
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rate of adverse effects in patients with AIDS could be related
to unusual pharmacokinetics.
After 3 weeks of treatment with pyrimethamine at 50 mg/
day, steady-state trough levels ranged from 0.8 to 2.92 mg/ml.
This range compares with steady-state trough levels of 1.3 to
4.4 mg/ml seen within patients not infected with HIV who were
treated with 25 mg of pyrimethamine twice a day (10). The
latter study used a bioassay and may have measured active
metabolites, thus overestimating pyrimethamine concentra-
tions. The finding that the trough levels in HIV-infected and
uninfected patients on similar regimens are similar is consis-
tent with the absence of significant differences in the pharma-
cokinetic parameters of HIV-infected patients.
Despite the use of a loading dose of 200 mg of pyrimeth-
amine, the mean trough level rose significantly between 7 and
14 days of therapy, from 1.58 to 1.77 mg/ml, and then stabilized.
In retrospect, this delay in achieving steady-state concentra-
tions is not surprising. On the basis of the average t1/2 of 139 h,
achieving steady state should require about 4 weeks in the
absence of a loading dose. At that time, peak concentrations
are expected to be about ninefold higher than the peak levels
after a single 50-mg dose. On the basis of the average V of 245
liters, a loading dose of 500 mg would be required to achieve
an initial peak level of approximately 2 mg/ml. Because such a
loading dose might prove intolerable, an alternate approach
might be to front-load with an accelerated initial regimen of
200 mg/day for the first 3 days. These approaches have not
been tried in patients, and it is not clear whether they could
lead to an increased incidence of adverse effects.
Noncompartmental and compartmental pharmacokinetic
analyses were performed. The results for the CL and AUC0–24
(a measure of the drug exposure attributable to a single dose at
steady state) were remarkably consistent for these two analy-
ses, both for the population and for individual subjects. Both
analyses provided an estimated mean CL of 1.3 6 0.4 liters/h
and an AUC0–24 of 42 6 12 mg z h/ml. For other pharmacoki-
netic parameters, these two analyses provided disparate esti-
mates. This may be due in part to the paucity of information on
kel, accurate estimation of which requires observations extend-
ing over several half-lives. Final observations were taken at 96
h on the basis of previously reported pyrimethamine half-lives
in HIV-infected patients (11, 24); however, both analyses
yielded an estimated mean t1/2 exceeding 96 h.
The fact that the previously reported short half-lives were
based on even shorter observation intervals of 10 to 48 h (11,
24) is of concern. If pyrimethamine has a significant distribu-
tion phase, so that pharmacokinetics are better described by a
two-compartment model, apparent half-lives measured over
short intervals would be likely to reflect a composite of distri-
bution and t1/2. Consistent with this, half-lives computed from
peak and trough levels were much shorter for a dosage of 50
mg/day than for a dosage of 100 mg/day. Although a distribu-
tive phase was not evident in many patients in the current
study, several patients did exhibit an apparent distributive
phase (e.g., Fig. 1b, c, and d), which would not be adequately
represented by a one-compartment model. However, our use
of a forecast interval approach to determine those points to be
included in the calculation of the terminal elimination rate
constant should have resulted in the rejection of points signif-
icantly affected by a distribution phase component.
From the population pharmacokinetic analysis based on the
one-compartment model, the mean pyrimethamine t1/2 was
estimated as 139 6 34 h, the AUC0–24 was 42.7 6 12.3 mg z h/
ml, the CL was 1.28 6 0.41 liters/h, the V was 246 6 64 liters,
and the ka was 1.5 6 1.3 liters/h. These parameter values are
similar to those of uninfected individuals, but with a somewhat
longer t1/2 resulting principally from a lower CL. With the
exception of the ka (which is usually difficult to estimate pre-
cisely in the fitting of nonlinear compartment models under
standard sampling protocols), the pharmacokinetic variability
of pyrimethamine is of the order of magnitude typical of most
drugs.
From the limited data available, no exceptionally large differ-
ences between the intravenous-drug-using and non-drug-using
HIV-infected populations emerged. There was no evidence of
a major pharmacokinetic interaction between pyrimethamine
and zidovudine. Although these conclusions are limited by the
small number of patients for whom data were available, very
large differences would have been detected, even if formal
significance was not achieved.
An unexpected finding of our study was a substantial rate
(73%) of adverse experience in the 3-week regimen, which
employed the standard 50-mg daily dose that is used for at least
6 weeks in the treatment of toxoplasma encephalitis. Ten of 26
patients (38%) permanently discontinued the study medication
because of nausea, headaches, or skin rash. An additional nine
patients (35%) experienced one of these adverse effects. There
were no differences between intravenous drug users and non-
users in the likelihood of having an adverse experience.
The observed range of pyrimethamine concentrations was
not substantially different from that seen in non-HIV-infected
persons. Because there was nothing to suggest that the study
TABLE 3. Summary statistics for zidovudine pharmacokinetic parameters determined by noncompartmental analysis
before and after coadministration of pyrimethaminea












Mean 869.11 1,265.42 0.6163 1.4132 1.9820 3.4803 651.55
Median 773.25 878.61 0.6110 1.1346 1.9196 3.0390 580.68
SD 440.88 1,360.86 0.2088 1.0850 0.8159 1.4058 361.60
CV (%) 50.7 107.5 33.9 76.8 41.2 40.4 55.5
With pyrimethamine
Mean 992.27 1,224.54 0.5583 1.4617 1.7654 3.9472 799.43
Median 821.74 1,069.82 0.6576 1.0553 1.7879 2.5903 587.41
SD 530.44 713.77 0.2031 0.6858 0.7722 3.3578 606.32
CV (%) 53.5 58.3 36.4 46.9 43.7 85.1 75.84
a Based on data for 10 subjects after a 100-mg oral dose of zidovudine.
b Cmax, maximum concentration observed.
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patients differed from the general HIV-infected population,
our results imply that this population may be relatively intol-
erant of pyrimethamine in the doses usually used to treat
toxoplasma encephalitis. Up to 40% of HIV-infected patients
with toxoplasma encephalitis treated with either pyrimeth-
amine-sulfadiazine or pyrimethamine-clindamycin have had
adverse drug reactions that required a change of therapy (3, 8).
Previously, skin rashes were usually thought to be related to
the clindamycin or sulfonamide component. In part, this was
supported by the observation that the rash usually resolved
when the patient was switched to the alternative treatment
regimen also containing pyrimethamine. However, the rash
may resolve despite continuation of the original regimen. This
occurred in one of our patients. Ruf et al. studied the pyri-
methamine-sulfadoxinecombinationtopreventrelapsesof toxo-
plasma encephalitis in 56 HIV-infected patients (21). Of 23
patients who developed a rash or pruritus, 19 elected to con-
tinue therapy with the same drugs. In all 19 patients, the skin
manifestations resolved.
Much of the previously reported intolerance to pyrimeth-
amine-sulfonamide or pyrimethamine-clindamycin in patients
with AIDS may in fact be related to pyrimethamine. Switching
to the alternate regimen may not always be necessary. Further
studies are needed to determine whether treating through
these adverse events, particularly skin rash, is feasible.
The frequencies of disabling nausea or vomiting and head-
aches were higher than those reported previously. These symp-
toms were not associated with higher serum pyrimethamine
concentrations or with the presence of abnormal liver chemis-
tries at baseline. Hematologic toxicity was uncommon during
this 3-week study. The coadministration of folinic acid may
have helped protect the bone marrow of patients.
We observed that pyrimethamine caused a predictable in-
crease in serum creatinine levels, confirming the findings of
Opravil et al. (19), who demonstrated that this increase re-
sulted from the inhibition of renal tubular secretion of creat-
inine by pyrimethamine. Clinicians should be aware that a mild
elevation in the serum creatinine level of a patient receiving
pyrimethamine usually does not indicate renal damage.
In conclusion, in this first formal pharmacokinetic study
of pyrimethamine in HIV-infected patients, there was great
variability in the concentrations of pyrimethamine in serum
achieved with a dosage of 50 mg daily, reflecting the variability
in CL rates. This suggests that drug level monitoring might be
useful during pyrimethamine therapy of toxoplasma encepha-
litis. However, additional studies are needed to determine
whether a therapeutic range can be established. In addition,
the steady-state drug levels were comparable to those in sim-
ilarly treated patients without HIV infection and the pyrimeth-
amine CL was no more rapid than in uninfected individuals.
No changes in the standard pyrimethamine treatment regi-
mens appear to be necessary for HIV-infected patients. The
t1/2 was typically more than 3 days. This suggests that a large
loading dose or an accelerated initial dosing regimen may be
desirable to rapidly achieve steady-state levels and that subse-
quent dosing need not be daily. A need for further investiga-
tion of such dosing regimens appears to be indicated.
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